Tirzepatide gets nod from US FDA

medwireNews: The FDA has approved the first-in-class, dual-action medication tirzepatide for glucose lowering in people with type 2 diabetes.

The decision is based on findings from the five clinical trials so far published from the SURPASS series. These showed significantly greater glucose reductions with tirzepatide compared with placebo, semaglutide, and insulin degludec and glargine in various study populations, as well as substantial reductions in bodyweight.

The cardiovascular outcomes trial – SURPASS-CVOT – is ongoing.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group